, the changes are as follows: - 1) total assets as of 31 December 2018 before retrospectively adjust was THB 14,329.7mn and after the retrospectively adjust was THB 14,376.4mn, an increase of THB 46.7mn

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

1,249.63 million and THB 729.06 million respectively. This equals to a sharp decline of 41.66% year on year. Domestic sales revenue dropped 43.82% from the same period of the previous year due to an

recorded total sales revenue of THB 733.57 million and THB 384.43 million respectively. This equals to a sharp decline of 47.59% year on year. Domestic sales revenue dropped 46.25% from the same period of

, the Company recorded total sales revenue of THB 983.36 million and THB 557.33 million respectively. This equals to a sharp decline of 4 3.32% year on year. Domestic sales revenue dropped 43.28% from the

benefit expenses For Quarter 2 of the year 2020, the management benefit was 3.24 million baht compare to 3.77 million baht, decrease by 0.53 million or 14.06% decreased because the company had adjust the

, end of June 30, 2020 Financial Statement Consolidate financial statement % Revenue from sales Q1/2020 Q1/2019 increase (decrease) Q1/2020 Q1/2019 Revenue from sales 85.68 121.53 (35.85) (29.50%) 100.00

2018, Sales revenue of the Company was recorded at THB 1,256.44 million and THB 983.36 million respectively or equivalent to a drop of 21.73% which is considered a consecutive decline from the last

for the year ended December 31, 2022, which details are as following; Operating results (Consolidated) Y2022 Y2021 % Increase (Decrease) Million Baht % Million Baht % Million Baht % Revenue from sales

believed that the reduce cost to net realisable value is adequate in the current circumstances. Source of fund Unit: Million Baht 31 March 2019 31 December 2018 Increase (decrease) % Variance Current